Literature DB >> 9553848

Humoral immune response to p53 in malignant glioma.

M Weller1, A Bornemann, M Ständer, M Schabet, J Dichgans, R Meyermann.   

Abstract

p53 immunoreactivity and humoral immune response to p53 were examined in 14 patients with malignant glioma, including 4 patients with leptomeningeal glioma cell dissemination. Twelve patients expressed p53 protein within the tumour tissue. p53 antibodies were detected in the serum in 2 of 14 patients but never in the cerebrospinal fluid (CSF). Soluble p53 protein was detected neither in serum nor in CSF of the glioma patients. CSF levels of the immunosuppressive cytokine, transforming growth factor (TGF)-beta, were elevated in the glioma patients, including those with a humoral response to p53. These preliminary findings raise the possibility of systemic humoral immune responses to antigens, including mutant p53, expressed by glioma cells in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9553848     DOI: 10.1007/s004150050199

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.

Authors:  S D Ryder; P M Rizzi; M Volkmann; E Metivier; L M Pereira; P R Galle; N V Naoumov; H Zentgraf; R Williams
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

2.  p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

Authors:  J Roth; D Dittmer; D Rea; J Tartaglia; E Paoletti; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

3.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.

Authors:  L V Crawford; D C Pim; R D Bulbrook
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

Review 4.  The p53 gene and its role in human brain tumors.

Authors:  O Bögler; H J Huang; P Kleihues; W K Cavenee
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

5.  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.

Authors:  K Angelopoulou; E P Diamandis; D J Sutherland; J A Kellen; P S Bunting
Journal:  Int J Cancer       Date:  1994-08-15       Impact factor: 7.396

6.  The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy.

Authors:  T Soussi
Journal:  Immunol Today       Date:  1996-08

7.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

Authors:  R Lubin; B Schlichtholz; D Bengoufa; G Zalcman; J Trédaniel; A Hirsch; C Caron de Fromentel; C Preudhomme; P Fenaux; G Fournier; P Mangin; P Laurent-Puig; G Pelletier; M Schlumberger; F Desgrandchamps; A Le Duc; J P Peyrat; N Janin; B Bressac; T Soussi
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

Review 8.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

9.  p53 protein is absent from the serum of patients with lung cancer.

Authors:  M A Levesque; M D'Costa; E P Diamandis
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

10.  Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone.

Authors:  M Weller; S Winter; C Schmidt; P Esser; A Fontana; J Dichgans; P Groscurth
Journal:  Int J Cancer       Date:  1997-11-27       Impact factor: 7.316

View more
  4 in total

Review 1.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

Review 2.  Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.

Authors:  Aravind Suppiah; John Greenman
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

3.  Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.

Authors:  A K M Ghulam Muhammad; Marianela Candolfi; Gwendalyn D King; Kader Yagiz; David Foulad; Yohei Mineharu; Kurt M Kroeger; Katherine A Treuer; W Stephen Nichols; Nicholas S Sanderson; Jieping Yang; Maksim Khayznikov; Nico Van Rooijen; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

4.  Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.

Authors:  Xisheng Li; Jun Yan; Rong Fan; Bin Luo; Qingmei Zhang; Yongda Lin; Sufang Zhou; Guorong Luo; Xiaoxun Xie; Shaowen Xiao
Journal:  Oncol Lett       Date:  2017-03-03       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.